Urodynamics With and Without the Use of Fluoroscopy
Practical overview of urodynamic studies with and without fluoroscopy, covering indications, key measurements, concerning findings, and patient preparation.
Read More
Topic: Bladder Cancer
Bladder Cancer Risk Factors and Prevalence
Anne E. Lizardi, DNP, CRNP, RNFA, reviews bladder cancer prevalence and key modifiable risk factors for clinicians.
Read More
Bladder Cancer Current Treatment Landscape
Anne E. Lizardi, DNP, CRNP, RNFA, reviews current guideline-based bladder cancer management, from intravesical therapy to systemic approaches.
Read More
Bladder Cancer Evaluation and Diagnosis
Anne E. Lizardi, DNP, CRNP, RNFA, details bladder cancer evaluation, cystoscopy, biomarkers, and imaging for diagnosis and staging.
Read MoreWSAUA 2025: Micro-Ultrasound (Micro-US), MRI, and PSMA PET in Prostate Cancer: Whole-Mount Correlation Study
Dr. Brisbane’s whole-mount correlation study compares micro-ultrasound (Micro-US), multiparametric MRI, and PSMA PET for detecting and staging prostate cancer. Results show Micro-US performs comparably to MRI for lesion detection, while MRI remains superior for assessing extracapsular extension. PSMA PET adds complementary but not superior diagnostic value.
Read More
Prostate Cancer Detection Biomarkers, MRI
Adam S. Kibel, MD, delves into strategies for prostate cancer detection, emphasizing the role of MRI and biomarkers in diagnostic accuracy.
Read More
Role of Immunotherapy for Upper Tract UC
Gopalkumar Iyer, MD, explores immunotherapy in upper tract urothelial carcinoma, emphasizing molecular distinctions from bladder cancer.
Read More
Bladder Cancer Journal Vol. 11, Issue 2 – April – June 2025
Higher resilience in radical cystectomy patients is associated with improved health related...
Read More
Role of DNA Repair Mutations in Sensitivity to Cisplatin-based Chemotherapy
Gopalkumar Iyer, MD, explores the role of genomic alterations in predicting response to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Read More
Grade Group 1 at Biopsy – Do We Need to Know More?
John W. Davis, MD, FACS, explores prostate cancer diagnostics and management, focusing on grade group one disease.
Read More
Updates to Microhematuria: AUA and SUFU Guidelines Update 2025
Diane K. Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PMD, discusses the newly released 2025 AUA/SUO/SUFFU guidelines on microhematuria evaluation.
Read More
Neoadjuvant Chemo vs. I/0 vs. ADCs
Daniel P. Petrylak, MD, explores neoadjuvant and adjuvant therapies in urothelial carcinoma in patients with muscle-invasive bladder cancer.
Read More